Role of the endogenous cannabinoid system in the formalin test of ersistent pain in the rat

European Journal of Pharmacology

Volumn 396, Issue 2-3, 2000, Pages 85-92

  Beaulieu, Pierre ^a   Bisogno, Tiziana ^b   Punwar, Shahid ^a   Farquhar Smith, W Paul ^a   Ambrosino, Gerolmina ^b   Di Marzo, Vincenzo ^b   Rice, Andrew S C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b CNR   (Italy)

Author keywords

2 Arachidonylglycerol; Anandamide; Cannabinoid CB1 receptor; Cannabinoid CB2 receptor; Cannabinoid receptor antagonist; Hyperalgesia; Inflammation; Nociception; Palmitoylethanolamide

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; AMIDASE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID CB1 RECEPTOR ANTAGONIST; CANNABINOID CB2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; FORMALDEHYDE; PALMIDROL; RECEPTOR SUBTYPE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HINDLIMB; HYPERALGESIA; INFLAMMATION; MALE; NONHUMAN; PAIN; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SKIN; STATISTICAL ANALYSIS; TISSUE LEVEL;

ANIMALS; BORNANES; ENDOCANNABINOIDS; FORMALDEHYDE; HYPERALGESIA; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RECEPTORS, DRUG;

EID: 0034685843     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00226-0     Document Type: Article

References (52)

1. Aloe L., Tuveri M., Cacassi U., Levi-Montalcini R. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum. 35:1992;351-355.
2. Barth F. Cannabinoid receptor agonists and antagonists. Exp. Opin. Ther. Patents. 8:1998;301-313.
3. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272:1997;3315-3323.
4. Bisogno T., Sepe N., Melck D., Maurelli S., De Petrocellis L., Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoyl-glycerol in mouse neuroblastoma cells. Biochem. J. 322:1997;671-677.
5. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernandez-Ruiz J.J., Di Marzo V. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 256:1999;377-380.
6. 1 receptor. Eur. J. Pharmacol. 374:1999;445-455.
7. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
8. 1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal neurones in the rat. Br. J. Pharmacol. 127:1999;1765-1767.
9. Compton D.R., Aceto M.D., Lowe J., Martin B.R. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity. J. Pharmacol. Exp. Ther. 277:1996;586-594.
10. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8375-8380.
11. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
12. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
13. Di Marzo V. 'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim. Biophys. Acta. 1392:1998a;153-175.
14. Di Marzo V., Bisogno T., Melck D., Ross R., Brockie H., Stevenson L., Pertwee R., De Petrocellis L. Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Lett. 436:1998b;449-454.
15. Dubuisson D., Dennis S.G. The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats. Pain. 4:1977;161-174.
16. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U. S. A. 92:1995;3376-3380.
17. 2 receptors. Soc. Neurosci. Abstr. 25:1999;373.2.
18. 1 receptor expression in rat spinal cord. Mol. Cell Neurosci. 2000;. in press.
19. Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232:1995;54-61.
20. 2, a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. U. S. A. 96:1999;14228-14233.
21. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
22. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221:1997;157-160.
23. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol. 81:1999;575-583.
24. Howlett A.C., Qualy J.M., Khachatrian L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313.
25. 2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
26. Kaminski N.E., Abood M.E., Kessler F.K., Martin B.R., Schatz A.R. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42:1992;736-742.
27. 1 receptor. Eur. J. Pharmacol. 334:1997;R1-2.
28. 1 receptor knockout mice. Science. 283:1999;401-404.
29. Lichtman A.H., Martin B.R. Spinal action of cannabinoid-induced antinociception. NIDA Res. Monogr. 105:1991;422-424.
30. 2 receptors. Br. J. Pharmacol. 124:1998;619-622.
31. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
32. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-Hydroxyethyl)hexadecanamide is orally active in reducing oedema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300:1996;227-236.
33. Mechoulam R., Fride E. The unpaved road to the endogenous brain cannabinoid ligands, the anandamides. Pertwee R.G. Cannabinoid Receptors. 1995;233-258 Academic Press, London.
34. Meng I.D., Manning B.H., Martin W.J., Fields H.L. An analgesia circuit activated by cannabinoids. Nature. 395:1998;381-383.
35. Munro S., Thomas K.L., Abu Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
36. 1 cannabinoid receptor activity. Mol. Pharmacol. 54:1998;1064-1072.
37. Richardson J.D., Aanonsen L., Hargreaves K.M. SR141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;R3-R4.
38. 1 receptors. Pain. 75:1998;111-119.
39. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D.et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. Febs Lett. 350:1994;240-244.
40. Rinaldi-Carmona M., Barth F., Heaulme M., Alonso R., Shire D., Congy C., Soubrie P., Brelière J.C., Le Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci. 56:1995;1941-1947.
41. 2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650.
42. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129:2000;227-230.
43. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav. 60:1998;183-191.
44. Strangman N.M., Patrick S.L., Hohmann A.G., Tsou K., Walker J.M. Evidence for a role of endogenous cannabinoids in the modulation of acute and tonic pain sensitivity. Brain Res. 813:1998;323-328.
45. Sulcova E., Mechoulam R., Fride E. Biphasic effects of anandamide. Pharmacol. Biochem. Behav. 59:1998;347-352.
46. Tjølsen A., Hole K. Animal models of analgesia. Dickenson A.H., Besson J.-M.R. The Pharmacology of Pain. 1997;1-20 Springer-Verlag, Berlin.
47. Tjølsen A., Berge O.G., Hunskaar S., Rosland J.H., Hole K. The formalin test: an evaluation of the method [see comments]. Pain. 51:1992;5-17.
48. Tominaga M., Caterina M.J., Malmberg A.B., Rosen T.A., Gilbert H., Skinner K., Raumann B.E., Basbaum A.I., Julius D. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 21:1998;531-543.
49. Watson G.S., Sufka K.J., Coderre T.J. Optimal scoring strategies and weights for the formalin test in rats. Pain. 70:1997;53-58.
50. Welch S.P., Huffman J.W., Lowe J. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J. Pharmacol. Exp. Ther. 286:1998;1301-1308.
51. 1 receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5780-5785.
52. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sørgård M., Di Marzo V., Julius D., Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.